Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 8/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | RHEB | Q15382 | 5/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23452389 | 0.98 | LOXL2 (0.38) | LOXL2MASP2F2RHEBCHUK | |
| SCHEMBL23452293 | 0.82 | RHEB (0.47) | MASP2F2RHEBCHUKADORA3 | |
| SCHEMBL23452513 | 0.82 | MASP2 (0.34) | MASP2F2RHEBCHUKADORA3 | |
| Hydrochloric Acid SCHEMBL30386861 | 0.81 | MASP2 (0.34) | MASP2F2RHEBCHUKADORA3 | |
| Hydrochloric Acid SCHEMBL28588197 | 0.81 | MASP2 (0.34) | MASP2F2RHEBCHUKADORA3 | |
| SCHEMBL31534617 | 0.73 | LOXL2 (0.52) | LOXL2RHEB | |
| SCHEMBL24493230 | 0.72 | CHUK (0.38) | CHUKADORA3ADORA2AADORA1 | |
| SCHEMBL23487157 | 0.72 | LMNA (0.37) | CHUKADORA3ADORA2AADORA1 | |
| SCHEMBL741480 | 0.69 | MAP2K1 (0.49) | RHEBCHUKADORA3ADORA2AADORA1 | |
| SCHEMBL31751076 | 0.68 | LOXL2 (0.38) | LOXL2RHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | LOXL2 1304/4885MASP2 1/4885F2 4221/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LOXL2 1380/4885MASP2 1/4885F2 4188/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LOXL2 1304/4885MASP2 1/4885F2 4221/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | LOXL2 1380/4885MASP2 1/4885F2 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.